Subtype
Pancreatic Exocrine Neoplasm
CI-CAN-00003563Explore in graph →
Non-malignant372 active trials5 approved drugs27 evidence items
- NCIt
- C4445
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003563Explore in graph →
Clinical trials
977 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02890355 | FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | May 20, 2026 | clinicaltrials |
| NCT07481357 | A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 | 51 | Dong-A ST Co., Ltd.INDUSTRY | 1 | May 20, 2026 |
| NCT05431270 | Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | recruiting | Phase 1 / Phase 2 | 40 | Phanes TherapeuticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | recruiting | Phase 2 | 320 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT06904378 | ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 61 | Washington University School of MedicineOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07594964 | To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors | recruiting | Phase 1 | 48 | Shenzhen Xinhe BiomedicalINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07595172 | NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 55 | West China HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT07592663 | Oncologic Safety and Lymphadenectomy in Parenchyma-Sparing Resection for SPN(PSR for SPN) | completed | — | 708 | Fudan UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07592819 | A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)(PRODIGE 104 B) | not yet recruiting | N/A | 367 | Institut Paoli-CalmettesOTHER | 0 | May 18, 2026 | clinicaltrials |
| NCT04137536 | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04927780 | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer(PREOPANC-3) | active not recruiting | Phase 3 | 378 | Erasmus Medical CenterOTHER | 2 | May 15, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT04789486 | Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05988918 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | active not recruiting | Phase 2 | 17 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06320990 | Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection(MCN_Tam) | recruiting | Phase 1 | 15 | University of NebraskaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | recruiting | Phase 1 / Phase 2 | 183 | Tango Therapeutics, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT03415854 | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)(NABPLAGEMD) | completed | Phase 2 | 34 | HonorHealth Research InstituteOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03767582 | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07532590 | Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content (PancreasPlus). | recruiting | N/A | 185 | Casa di Cura Dott. PederzoliOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03851237 | CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy | completed | Phase 1 | 69 | Washington University School of MedicineOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04331041 | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | active not recruiting | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04627246 | Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer | active not recruiting | Phase 1 | 14 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07554560 | Nutrition Intervention for Pancreatic Cancer | recruiting | N/A | 18 | Children's Hospital of PhiladelphiaOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04881487 | Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy(ARCADE) | recruiting | N/A | 174 | UMC UtrechtOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | terminated | Phase 1 | 68 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT07566897 | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 96 | Philogen S.p.A.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT02072616 | Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.(CTC-Pancreas) | terminated | N/A | 101 | University Hospital, RouenOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 4, 2026 | clinicaltrials |
| NCT05296421 | Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer | recruiting | N/A | 16 | Rutgers, The State University of New JerseyOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06015659 | ZN-c3 + Gemcitabine in Pancreatic Cancer | active not recruiting | Phase 2 | 12 | Brandon Huffman, MDOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07561463 | Sacituzumab Tirumotecan for Pancreatic Cancer | not yet recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT06648434 | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 | 51 | Washington University School of MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07478523 | FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers(FAPDIG) | recruiting | Phase 2 | 120 | University Hospital, BordeauxOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02495896 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 61 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03033927 | Predicting Effective Therapy in Pancreatic Cancer | active not recruiting | — | 74 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06381882 | The Role of the Human Microbiome in Patients After Pancreatic Resection.(MiPac) | enrolling by invitation | — | 200 | St. Antonius HospitalOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06549725 | Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening | recruiting | N/A | 419 | Lipidica, a.s.INDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07408505 | Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer | recruiting | N/A | 56 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT00669734 | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06483555 | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel(PANGEA) | recruiting | Phase 1 / Phase 2 | 104 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07547033 | Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy(EQUINOXE) | not yet recruiting | N/A | 150 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03138720 | Pre-operative Treatment for Patients With Untreated Pancreatic Cancer | completed | Phase 2 | 40 | HonorHealth Research InstituteOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05973331 | Prospective Validation of an EHR-based Pancreatic Cancer Risk Model | active not recruiting | — | 6,134,060 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT06330441 | Pancreatic Cancer Screening in a Population at High Risk(ScrePan) | recruiting | N/A | 700 | Masaryk Memorial Cancer InstituteOTHER | 1 | Apr 21, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 20, 2026source: clinicaltrials